MY114942A - Method for treatment of chronic bronchitis using indole compounds - Google Patents

Method for treatment of chronic bronchitis using indole compounds

Info

Publication number
MY114942A
MY114942A MYPI98001273A MYPI9801273A MY114942A MY 114942 A MY114942 A MY 114942A MY PI98001273 A MYPI98001273 A MY PI98001273A MY PI9801273 A MYPI9801273 A MY PI9801273A MY 114942 A MY114942 A MY 114942A
Authority
MY
Malaysia
Prior art keywords
treatment
chronic bronchitis
indole compounds
indole
compounds
Prior art date
Application number
MYPI98001273A
Other languages
English (en)
Inventor
William Louis Macias
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY114942A publication Critical patent/MY114942A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
MYPI98001273A 1997-03-26 1998-03-24 Method for treatment of chronic bronchitis using indole compounds MY114942A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4210197P 1997-03-26 1997-03-26

Publications (1)

Publication Number Publication Date
MY114942A true MY114942A (en) 2003-02-28

Family

ID=21920055

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI98001273A MY114942A (en) 1997-03-26 1998-03-24 Method for treatment of chronic bronchitis using indole compounds

Country Status (8)

Country Link
US (1) US5972988A (enExample)
EP (1) EP1007046A4 (enExample)
JP (1) JP4347914B2 (enExample)
AU (1) AU6771798A (enExample)
CA (1) CA2284757A1 (enExample)
MY (1) MY114942A (enExample)
WO (1) WO1998042343A1 (enExample)
ZA (1) ZA982454B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2308443A1 (en) * 1997-10-27 1999-05-06 Michael Lyle Denney Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
EP1030661A4 (en) * 1997-10-27 2002-07-17 Lilly Co Eli N, N-DIETHYLGLYCOLAMIDOESTER OF INDOLS AS PRELIMINARY MEDICINE OF SPLA 2 INHIBITORS
CZ302588B6 (cs) * 1998-04-02 2011-07-27 Ziopharm Oncology, Inc. Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva
US6576654B1 (en) * 1998-09-23 2003-06-10 Eli Lilly And Company Method for the treatment of cystic fibrosis
US6274578B1 (en) 1999-04-20 2001-08-14 Eli Lilly And Company sPLA2 inhibitor ester
US6140327A (en) * 1999-05-12 2000-10-31 Eli Lilly And Company Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
WO2001044185A1 (en) * 1999-12-16 2001-06-21 Eli Lilly And Company Carbon monoxide-based synthesis of spla2 inhibitors
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
WO2001081306A2 (en) * 2000-04-19 2001-11-01 Eli Lilly And Company Azide cyclization-based synthesis and intermediates for spla2 inhibitors
US20060035811A1 (en) * 2002-10-18 2006-02-16 Luis Molina Methods of treating dry eye disease with lantibiotics
CN1747936A (zh) * 2003-02-12 2006-03-15 特兰斯泰克制药公司 作为治疗试剂的取代吡咯衍生物
CA2565457A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
US20150338425A1 (en) * 2011-11-14 2015-11-26 The Brigham And Women's Hospital, Inc. Treatment and prognosis of lymphangioleiomyomatosis
US9925202B2 (en) 2013-03-04 2018-03-27 Brigham And Women's Hospital, Inc. Treatment of lymphangioleiomyomatosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2341045A1 (en) * 1994-04-01 2011-07-06 Eli Lilly and Company [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor

Also Published As

Publication number Publication date
JP4347914B2 (ja) 2009-10-21
AU6771798A (en) 1998-10-20
EP1007046A4 (en) 2000-11-29
WO1998042343A1 (en) 1998-10-01
ZA982454B (en) 1999-09-23
JP2001524962A (ja) 2001-12-04
CA2284757A1 (en) 1998-10-01
EP1007046A1 (en) 2000-06-14
US5972988A (en) 1999-10-26

Similar Documents

Publication Publication Date Title
MY114942A (en) Method for treatment of chronic bronchitis using indole compounds
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
AU696851B2 (en) Method of treating hyperproliferative vascular disease
BG102425A (en) (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors
AU3713795A (en) Device for acclimatization to therapy by injections
GEP20022616B (en) (54) Azepin Derivatives to Inhibiting Farnesyl Protein Transferase and Method for Treatment
GR3026344T3 (en) Method for treating an lfa-1-mediated disorder.
MY119375A (en) Treatment of tinnitus using neuroprotective agents
AU1711197A (en) Method for treating sexual dysfunctions
AU2251901A (en) Methods and compounds for inhibiting MRP1
WO1990009993A3 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
GR1003189B (el) Μεθοδοι προληψεως του καρκινου του μαστου
PL334500A1 (en) Methods of therapeutically administering substances acting against cd40l
GB9727131D0 (en) Therapeutic agents
IL98574A0 (en) Piperidyl-substituted indoles
WO2001080813A3 (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
GR3030262T3 (en) Compositions and methods using unbound mpl receptor for stimulating platelet production
AU6311498A (en) Hgf for treating acute renal failure
NZ511559A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
GR3023645T3 (en) Treatment of liver cancer
TR200003194T2 (tr) Hastalık tedavisine mahsus sPLA2 önleyici bileşikler
AU4530796A (en) Treating disorders characterised by excessive cell proliferation with sclareolide
BG103779A (en) Crystallohydrate sodium salt of (e)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidine-3-ilidenmethyl)-1h-i ndole-2-carboxylic acid